Competition to preoccupy Viread generic market of KRW 150 billion
It’s Viread for now. After Baraclude generics, domestic pharmaceutical companies are directly aiming for Viread whose substance patent is expiring soon on November next year.
Viread is a product which become the largest product after taking over the Baraclude’s 7-year throne as a hepatitis B tre...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
